Clinical Microbiology Newsletter
Volume 30, Issue 20 , Pages 151-158, 15 October 2008

Opportunistic Free-living Amebae, Part I1

  • G.S. Visvesvara, Ph.D.

      Affiliations

    • Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationMailing Address: Govinda S. Visvesvara, Ph.D., Division of Parasitic Diseases, Chamblee Campus, Bldg. 109, M.S.-F-36, 4770 Buford Highway NE, Atlanta, GA 30341-3724. Tel.: 770-488-4417. Fax: 770-488-4253
  • ,
  • F.L. Schuster, Ph.D.

      Affiliations

    • Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California

Abstract 

The free-living amebae Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri have been recognized as etiologic agents of amebic encephalitis. Although each has its own morphologic, ecologic, and epidemiologic traits, they have in common the ability to tolerate mammalian body temperature and cause infections. The amebic diseases are difficult to diagnose clinically, leading to delay in treatment, resulting in a high mortality rate. The major tests for the diagnosis of these diseases include immunostaining for amebae in brain and other tissues and conventional and real-time PCR. Because the number of reported cases is low, only a handful of laboratories are equipped for performing such testing. Acanthamoeba causes systemic infections mainly in immunocompromised individuals but can also cause corneal infections in healthy individuals who wear contact lenses. In Part I of this article, the general characteristics of Acanthamoeba are reviewed, as well as its cultivation, the diseases it causes, the pathophysiology of infections, mechanisms of pathogenesis, therapy and prognosis, and, finally, prevention and control. In addition, the general characteristics of B. mandrillaris, which causes a subacute though deadly infection in either healthy or immunocompromised hosts, is discussed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  • 1 Editor's Note: Part II of this article will be published in the November 1, 2008 issue of CMN (Vol. 30, No. 21).

 Editor's Note: Part II of this article will be published in the November 1, 2008 issue of CMN (Vol. 30, No. 21).

PII: S0196-4399(08)00051-2

doi:10.1016/j.clinmicnews.2008.09.004

Clinical Microbiology Newsletter
Volume 30, Issue 20 , Pages 151-158, 15 October 2008